Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Official Title

A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome

Brief Summary

      Rett syndrome is a severe neurodevelopmental disorder that primarily affects female children.
      Rett syndrome is characterized by significant elevation in blood markers of oxidative stress.
      EPI-743 is a novel therapeutic with demonstrated efficacy and safety in the treatment of
      disorders characterized by oxidative stress. The purpose of this study is to examine the
      safety and efficacy of EPI-743 in a population of children with Rett syndrome.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Rett Syndrome Clinical Severity Sore

Secondary Outcome

 Oxidative Stress Biomarkers

Condition

Rett Syndrome

Intervention

EPI-743

Study Arms / Comparison Groups

 EPI-743 15 mg/kg
Description:  Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

January 2013

Completion Date

January 2014

Primary Completion Date

December 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Diagnosis of Rett syndrome with disease stage 1-2

          -  Abnormality of at least two disease biomarker levels

          -  Confirmed MeCP2 mutation

          -  Patient or patient's guardian able to consent and comply with protocol requirements

          -  Abstention from use of Coenzyme Q10, vitamin E and Idebenone two weeks prior to
             enrollment into the study

        Exclusion Criteria:

          -  Any condition, which in the opinion of the investigator could compromise the subject's
             safety or adherence to treatment with EPI-743.

          -  Clinically significant allergy or hypersensitivity to EPI-743 or to any of the
             excipients of with EPI-743 (eg., sesame oil).

          -  Clinically significant allergy or hypersensitivity to Vitamin E

          -  Lack of confirmation of MeCP2 mutation

          -  Clinical history of bleeding or abnormal baseline PT/PTT

          -  Diagnosis of any other concurrent inborn error of metabolism

          -  Hepatic insufficiency with LFTs greater than 3 times upper limit of normal

          -  Renal insufficiency requiring dialysis

          -  End stage cardiac failure

          -  Fat malabsorption syndromes precluding drug absorption
      

Gender

Female

Ages

N/A - 18 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Italy

Location Countries

Italy

Administrative Informations


NCT ID

NCT01822249

Organization ID

OPBGC&RS_12_003


Responsible Party

Sponsor

Study Sponsor

Edison Pharmaceuticals Inc


Study Sponsor

, , 


Verification Date

July 2018